CONTACT US
FOLLOW US
Linkedin X
Prothena
  • About Us
    • Overview
    • Our History
    • Leadership
    • Board of Directors
    • Quality Policy
    • Partnering
  • Our Science
    • Overview
    • Publications
  • Pipeline
    • Overview
    • AL Amyloidosis
    • Parkinson’s Disease
    • ATTR Amyloidosis
    • Alzheimer’s Disease
  • Clinical Trials
    • Overview
    • Birtamimab
    • Prasinezumab
    • Coramitug (PRX004)
    • BMS-986446 (PRX005)
    • PRX012
    • Expanded Access Policy
  • News Center
    • News Center
    • Featured Articles
    • Press Releases
    • Photos/Videos
    • Fact Sheets
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financials & Filings
    • Corporate Governance
    • Stock Information
    • Analyst Coverage
  • Careers
    • Overview
    • Our Values
    • Compensation & Benefits
    • Opportunities
  • Menu Menu
  • Menu Menu

© 2025 Prothena | Terms of Use | Privacy Policy | Cookie Policy |

Scroll to top

US Healthcare Professional Confirmation

 

The purpose of this resource is to provide information to US healthcare professionals (HCPs) about Prothena’s investigational drug candidates.

This resource contains medical and scientific information related to Prothena’s products and/or uses that have not been approved by any regulatory authority (e.g., FDA, EMA).

If you are a patient or caregiver, please discuss any medical or treatment questions with your healthcare provider.

All Prothena drugs (wholly-owned or partnered) referenced herein are investigational drugs and not approved by any regulatory authority.